We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Moderna Inc
628 own
288 watching
Current Price
$176.06
$-4.81
(-2.66%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
68,135.22M
52-Week High
217.25
52-Week Low
115.03
Average Volume
6.21M
Dividend Yield
--
P/E Ratio
14.5666
Market Capitalization68,135.22M52-Week High217.2552-Week Low115.03Average Volume6.21MDividend Yield--P/E Ratio14.5666What does the Moderna Inc do?
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Moderna Inc make?
News & Events about Moderna Inc.
Zolmax
2days ago
Moderna, Inc. (NASDAQ:MRNA Get Rating) Director Noubar Afeyan sold 10,000 shares of the companys stock in a transaction on Wednesday, January 25th. The shares were sold at an average price of $194.33, for a total transaction of $1,943,300.00. Following the completion of the transaction, the director...
Accesswire
2days ago
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adultsCAMBRIDGE, MA / ACCESSWIRE / January 30, 2023 /Moderna, Inc...
Ticker Report
9days ago
Moderna, Inc. (NASDAQ:MRNA Get Rating) CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $192.06, for a total transaction of $7,682,400.00. Following the sale, the chief executive ...
Zero Hedge
10days ago
Elon Musk Reveals "Major Side Effects" After 2nd COVID Booster
Authored by Allen Zhong via The Epoch Times,
Elon Musksaid he felt like he was dying after his second COVID-19boostershot.
I had majorside effectsfrom my second booster shot, the new Twitter boss wrote in a social media post.
Felt ...
Benzinga
14days ago
With US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Moderna Inc share price today?
Can Indians buy Moderna Inc shares?
How can I buy Moderna Inc shares from India?
Can Fractional shares of Moderna Inc be purchased?
What are the documents required to start investing in Moderna Inc stocks?
What is today’s traded volume of Moderna Inc?
What is today’s market capitalisation of Moderna Inc?
What is the 52-Week High and Low Range of Moderna Inc?
What percentage is Moderna Inc down from its 52-Week High?
What percentage is Moderna Inc up from its 52-Week Low?
Current Price
$176.06
$-4.81
(-2.66%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.